Clinical Trial

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Study acronym: TRIPS
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-02-24; most recent amendment 2026-03-11.
Status change: Not Yet Recruiting → Recruiting 2022-10-03
Trial Details
NCT Number NCT05267821
Lead Sponsor Nationwide Children's Hospital
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Enrollment 500 participants
Start Date 2022-06-14
Primary Completion 2028-05-15 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13